|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM178418099 |
| 003 |
DE-627 |
| 005 |
20231223152054.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2008 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2008.02.001
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0595.xml
|
| 035 |
|
|
|a (DE-627)NLM178418099
|
| 035 |
|
|
|a (NLM)18358784
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Bontkes, Hetty J
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells
|
| 264 |
|
1 |
|c 2008
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 07.07.2008
|
| 500 |
|
|
|a Date Revised 23.05.2008
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Immunotherapy aiming at the combined activation of tumor associated antigen (TAA) specific cytotoxic T lymphocytes (CTL) and Natural Killer (NK) cells may be crucial to eradicate both MHC-I positive and negative tumors. Vaccination with mature dendritic cells (DC) transfected with mRNA encoding for TAA and the pro-inflammatory cytokines interleukin (IL)-12 and IL-18 may increase NK cell and TAA specific CTL activity. We demonstrate here that IL-12 over-expressing human DC induces increased NK cell activation and effector function and confirm the increase in TAA specific CTL by TAA/IL-12 double transfected DC. The effects of IL-18 transfection were limited to phenotypic activation and down-regulation of tissue homing receptors and did not add to the effect of IL-12 on NK cell effector function. In conclusion, co-transfection of TAA and IL-12 mRNA into mature DCs offers a vaccine for the induction of an anti-tumor immune response mediated by CTL and NK effector cells
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antigens, Neoplasm
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-18
|2 NLM
|
| 650 |
|
7 |
|a RNA, Messenger
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Cytokine
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-12
|2 NLM
|
| 650 |
|
7 |
|a 187348-17-0
|2 NLM
|
| 700 |
1 |
|
|a Kramer, Duco
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ruizendaal, Janneke J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Meijer, Chris J L M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hooijberg, Erik
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 127(2008), 3 vom: 01. Juni, Seite 375-84
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:127
|g year:2008
|g number:3
|g day:01
|g month:06
|g pages:375-84
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2008.02.001
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 127
|j 2008
|e 3
|b 01
|c 06
|h 375-84
|